• Brii Bio flagged ongoing arbitration with Vir Biotechnology over elebsiran manufacturing technology transfer, creating uncertainty for the elebsiran program.
• Phase 3 advancement of the ENRICH regimen remains contingent on resolving the dispute.
• Brii Bio said it cannot fund any Phase 3 elebsiran-containing HBV study unless the arbitration claims are satisfactorily resolved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607022000PR_NEWS_USPR_____CN97125) on July 03, 2026, and is solely responsible for the information contained therein.